Microsoft Tablets to COMPETE Against PC Makers and 3 Dow Movers Turning Heads

Merck & Co. Inc. (NYSE:MRK): The United States Supreme Court might take up the issue of pharmaceutical firms paying rivals to postpone selling generic drugs, after a Federal judge ruled earlier in July that they can not, according to a Thursday New York Times report.

Don’t Miss: Merck Earnings: Expands Margins AGAIN, TOPS Analyst Estimates.

Microsoft Corporation (NASDAQ:MSFT) concluded in its annual report submitted Thursday afternoon, that its new Surface tablet might possibly undermine PC maker support for Windows, as its devices will compete against tablets that they sell, says the New York Times.

Pfizer Incorporated’s (NYSE:PFE) jointly developed Alzheimer therapy bapineuzumab showed disappointing results, and the two other drug firms, Elan Corp. (ELIN) and Johnson & Johnson (NYSE:JNJ), who helped with the project, are seeing their shares down in reaction as well, according to Bloomberg. The situation leaves Elan with only one major product, namely the multiple sclerosis treatment Tysabri, which Biogen (NASDAQ:BIIB) co-owns, all of which prompts the $7.1 billion firm for a deal with Biogen, think Jefferies Group and Royal Bank of Canada.

Wal-Mart Stores Inc. (NYSE:WMT), along with some other retailers have already prepared defenses, in case the Justice Department and the Securities and Exchange Commission initiates an inquiry into the retail industry for violations of an anti-foreign bribery law, according to Reuters.

Don’t Miss: Apple’s Kodak Strategy FAILS.

Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.